Dual targeting T cell candidate mosunetuzumab has been granted Breakthrough Therapy designation from the US regulator.
It is the tenth such designation for the hematology portfolio of Swiss cancer giant Roche (ROG: SIX) from the Food and Drug Administration. The designation enables expedited review of candidates for serious conditions which have promising early data.
Encouraging efficacy results have been observed in the Phase I/Ib GO29781 study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze